Celgene Corp has agreed to pay $55 million to resolve claims that the drugmaker engaged in an multi-faceted scheme to maintain a monopoly over the market for its cancer treatment drugs Thalomid and Revlimid and delay generic competition.
The settlement was disclosed in a filing on Wednesday in federal court in Newark, New Jersey, and would, if approved, resolve a class action brought on behalf of insurers, consumers and others who claimed they paid more for the drugs than they should have.
